YusufYaziciMD

PubMed

• Introduction, Vasculitis 2023.
  Hasan Yazici, Yusuf Yazici> ;Current Opinion in Rheumatology. 2024 Jan 1
• 1 citations
  Are Disease Classification Criteria for Diagnosis or for Research? In Fact, for Neither.
  Hasan Yazici, Yusuf Yazici> ;The Journal of Rheumatology. 2024 Feb 1
• Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel...
  Mark S Fineman, Timothy E McAlindon, Christian Lattermann, Christopher J Swearingen, Sarah Kennedy, Victor A Lopez, Ismail Simsek, Jeyanesh R S Tambiah, Yusuf Yazici> ;Rheumatology and Therapy. 2023 Dec 1
• Current treatment approach to ANCA-associated vasculitis.
  Yusuf Yazici> ;Current Opinion in Rheumatology. 2024 Jan 1
• 3 citations
  Behçet Syndrome.
  Gülen Hatemi, Didar Uçar, Uğur Uygunoğlu, Hasan Yazici, Yusuf Yazici> ;Rheumatic Diseases Clinics of North America. 2023 Aug 1
• 1 citations
  Outcome measures in Behçet syndrome.
  Gülen Hatemi, Yusuf Yazici> ;Clinical Immunology. 2023 Jun 1
• A probable ecologic bias in the article on the progression of knee osteoarthritis: comment on the article by Lo et al.
  Hasan Yazici, Hande Ogun, Yusuf Yazici> ;Arthritis & Rheumatology. 2023 Sep 1
• 2 citations
  Difficult-to-treat Behçet syndrome: A therapeutic approach.
  Yusuf Yazici, Gulen Hatemi> ;Clinical Immunology. 2023 Apr 1
• 1 citations
  Should quantitative assessment of rheumatoid arthritis include measures of joint damage and patient distress, in addition to measures of apparent inflammatory activity?
  Theodore Pincus, Juan Schmukler, Joel A Block, Nicola Goodson, Yusuf Yazici> ;ACR Open Rheumatology. 2023 Jan 1
• 4 citations
  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic a...
  Hasan Yazici, Koray Tascilar, Yusuf Yazici> ;Current Opinion in Rheumatology. 2023 Jan 1
• 3 citations
  Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
  Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Doyoung Kim, Melike Melikoğlu, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazici> ;RMD Open. 2022 Jul 1
• 1 citations
  A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody-related vasculitis criteria sets: comment on criteria sets ap...
  Hasan Yazici, Yusuf Yazici> ;Arthritis & Rheumatology. 2022 Oct 1
• Editorial: Introduction, Vasculitis 2021.
  Hasan Yazici, Yusuf Yazici> ;Current Opinion in Rheumatology. 2022 Jan 1
• 1 citations
  Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity
  Theodore Pincus, Martin J. Bergman, Yusuf Yazici> ;The Journal of Rheumatology. 2021 Oct 15
• 52 citations
  Behçet syndrome.
  Yusuf Yazici, Gulen Hatemi, Bahram Bodaghi, Jae Hee Cheon, Noburu Suzuki, Nicola Ambrose, Hasan Yazici> ;Nature Reviews. Disease Primers. 2021 Sep 16
• 2 citations
  Initial visit symptoms in probable Behçet's syndrome is predictive of ISG criteria fulfillment in Behçet's syndrome: data from New York and Amsterdam cohorts.
  F. Kerstens, F. Turkstra, C. Swearingen, Yusuf Yazici> ;Clinical and Experimental Rheumatology. 2021 Sep 1
• Effect size, the misnomer.
  Hasan Yazici, Yusuf Yazici> ;Clinical and Experimental Rheumatology. 2021 Sep 7
• 13 citations
  Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
  Gulen Hatemi, A. Mahr, Mitsuhiro Takeno, Do Young Kim, David Saadoun, Haner Direskeneli, Melike Melikoglu, S. Cheng, Shannon McCue, Maria Paris, M. Chen, Yusuf Yazici> ;Clinical and Experimental Rheumatology. 2021 Sep 1
• 9 citations
  Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.
  Jeyanesh Tambiah, S. Kennedy, C. Swearingen, Ismail Simsek, Yusuf Yazici, Jack Farr, Philip G. Conaghan> ;Rheumatology and Therapy. 2021 Jun 8
• Concerns Regarding the Analysis of a Takayasu Arteritis Cohort: Comment on the Article by Goel et al.
  Hasan Yazici, Mert Oztas, Yusuf Yazici> ;Arthritis & Rheumatology. 2021 May 13
• 40 citations
  A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
  Yusuf Yazici, Timothy E. McAlindon, Allan Gibofsky, Nancy E Lane, Christian Lattermann, N. Skrepnik, Christopher J. Swearingen, Ismail Simsek, Heli Ghandehari, A. DiFr...> ;Osteoarthritis and Cartilage. 2021 May 1
• 1 citations
  Comment on: 'It can't be zero!' Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study.
  Theodore Pincus, Kathryn A. Gibson, Yusuf Yazici, Martin J. Bergman, Juan Schmukler, Joel A. Block> ;Rheumatology. 2021 Jan 5
• 18 citations
  The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome.
  Gulen Hatemi, Alexa Meara, Yesim Ozguler, Haner Direskeneli, A. Mahr, Beverly Shea, Esen Cam, Ahmet Gül, Yusuf Yazici, Peter Tugwell, Hasan Yazici, Peter A. Merkel> ;Arthritis Care & Research. 2020 Nov 17
• 22 citations
  SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy.
  V. Deshmukh, T. Seo, Alyssa L O'Green, Maureen Ibanez, Brian Joseph Hofilena, Sunil Kumar Kc, Joshua Stewart, Dellamary Luis A, Kevin Chiu, Abdullah Ghias, Charlene F....> ;Journal of Orthopaedic Research. 2021 Sep 1
• 75 citations
  Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Tr...
  Yusuf Yazici, Timothy E. McAlindon, Allan Gibofsky, Nancy E Lane, Daniel J. Clauw, Morgan H. Jones, John A. Bergfeld, Christopher J. Swearingen, A. DiFrancesco, Ismail...> ;Arthritis & Rheumatology. 2020 Oct 1
• Join now to see all